Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.55 |
| ▸ | STAT6 | P42226 | 1/20 | 0.55 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2717718 | 0.98 | LMNA (0.56) | LMNAGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL1497406 | 0.76 | LMNA (0.55) | LMNAGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL12758978 | 0.76 | GRIN1 (0.55) | LMNAGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL13968149 | 0.76 | LMNA (0.43) | LMNAGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL13717334 | 0.73 | EPHX2 (0.48) | TSHREPHX2NPSR1 | |
| Amantadine SCHEMBL15532073 | 0.73 | GRIN1 (1.00) | LMNAGRIN1GRIN2AGRIN2DGRIN3B | |
| Amantadine SCHEMBL15672299 | 0.73 | GRIN1 (1.00) | LMNAGRIN1GRIN2AGRIN2DGRIN3B | |
| Amantadine SCHEMBL21309814 | 0.73 | GRIN1 (1.00) | LMNAGRIN1GRIN2AGRIN2DGRIN3B | |
| Amantadine SCHEMBL21310017 | 0.73 | GRIN1 (1.00) | LMNAGRIN1GRIN2AGRIN2DGRIN3B | |
| Amantadine SCHEMBL3642447 | 0.73 | GRIN1 (1.00) | LMNAGRIN1GRIN2AGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402920-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| CN-107556244-B | Fused ring compound, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| WO-2013086131-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086131-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-13 | — | — | WO | disclosed |
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120295886-A1 | ANTIVIRAL COMPOUNDS AND THEIR METHODS OF USE | INFLUMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295886-A1 | ANTIVIRAL COMPOUNDS AND THEIR METHODS OF USE | INFLUMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295886-A1 | ANTIVIRAL COMPOUNDS AND THEIR METHODS OF USE | INFLUMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012059932-A1 | 2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012059932-A1 | 2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-10 | — | — | WO | disclosed |
| US-20110318542-A1 | Fluorine-Containing Compound, Fluorine-Containing Polymer Compound, Resist Composition and Patterning Method Using Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
| US-4816453-A | N-heterocyclic derivatives of benzamides and their use in treating gastric and intestinal disorders | BEECHAM GROUP, P.L.C. (GB) | 1989-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | HAVCR2, HDLBP, HSP90B1 | LMNA 1831/4885GRIN1 2486/4885GRIN2A 3238/4885 |
| US-20120295886-A1 | ANTIVIRAL COMPOUNDS AND THEIR METHODS OF USE | MAVS, H1-2, ATP6AP1 | LMNA 1527/4885GRIN1 665/4885GRIN2A 697/4885 |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | MAVS, SLC30A5, HAVCR2 | LMNA 1701/4885GRIN1 2482/4885GRIN2A 2171/4885 |
| US-20110318542-A1 | Fluorine-Containing Compound, Fluorine-Containing Polymer Compound, Resist Composition and Patterning Method Using Same | FRG1, AFF2, AFF1 | LMNA 2479/4885GRIN1 756/4885GRIN2A 720/4885 |
| US-20220402920-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | DPYD, PNP, TYMP | LMNA 1281/4885GRIN1 3883/4885GRIN2A 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.